Research

GSK completes acquisition of Sierra Oncology

GSK plc (LSE/NYSE: GSK) announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.

Researchers discover new leukemia-killing compounds

Researchers from Rice University and the University of Texas MD Anderson Cancer Center have discovered potential new drugs that work in concert with other drugs to deliver a deadly one-two punch to leukemia.

The potential drugs are still years away from being tested in cancer patients, but a recently published study in the journal Leukemia highlights their promise and the innovative methods that led to their discovery.

New approach to treatment of deadly kidney cancer

Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment. Their findings, which are published in Nature Metabolism, offer hope for more targeted cancer drugs.

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.

A new technology offers treatment for HIV infection through a single injection

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The study examined the engineering of type B white blood cells in the patient's body so as to secrete anti-HIV antibodies in response to the virus.

Proteomic study of 2,002 tumors identifies 11 pan-cancer molecular subtypes across 14 types of cancer

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowledge that greatly expands a searchable online database that has become a go-to platform for cancer data analysis by users worldwide.

Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on the evolving treatment of rectal cancer. She offers prospects for future treatment of the disease in light of encouraging findings from a study published in the journal that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.

Research & Development

GSK completes acquisition of Sierra Oncology

Researchers discover new leukemia-killing compounds

New approach to treatment of deadly kidney cancer

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

A new technology offers treatment for HIV infection through a single injection

Proteomic study of 2,002 tumors identifies 11 pan-cancer molecular subtypes across 14 types of cancer

Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine

More Pharma News ...